95 related articles for article (PubMed ID: 7498466)
1. A novel approach to the design of potent bioactive peptides by incorporation of proline brackets: antiplatelet effects of Arg-Gly-Asp peptides.
Kini RM; Evans HJ
FEBS Lett; 1995 Nov; 375(1-2):15-7. PubMed ID: 7498466
[TBL] [Abstract][Full Text] [Related]
2. [The structure-antiaggregative activity relationship in a series of Arg-Gly-Asp analogs].
Mel'nik OV; Martinovich VP; Golubovich VP
Bioorg Khim; 2006; 32(2):137-43. PubMed ID: 16637284
[TBL] [Abstract][Full Text] [Related]
3. Development of a novel potent peptidyl platelet preserving agent: molecular design and biologic activity.
Ozeki E; Matsuda T
ASAIO Trans; 1990; 36(3):M562-4. PubMed ID: 2252751
[TBL] [Abstract][Full Text] [Related]
4. Hybrid peptide containing RGDF (Arg-Gly-Asp-Phe) coupled with the carboxy terminal part of alpha 2-antiplasmin capable of inhibiting platelet aggregation and promoting fibrinolysis.
Udvardy M; Schwartzott D; Jackson K; McKee PA
Blood Coagul Fibrinolysis; 1995 Feb; 6(1):11-6. PubMed ID: 7795148
[TBL] [Abstract][Full Text] [Related]
5. Synthesis of cyclic oligopeptides containing an Arg-Gly-Asp (RGD) sequence.
Sofuku S; Hoshida A; Shimada T; Takada Y; Takakuwa T
Chem Pharm Bull (Tokyo); 1999 Dec; 47(12):1799-801. PubMed ID: 10748723
[TBL] [Abstract][Full Text] [Related]
6. Potent in vitro and in vivo inhibitors of platelet aggregation based upon the Arg-Gly-Asp-Phe sequence of fibrinogen. A proposal on the nature of the binding interaction between the Arg-guanidine of RGDX mimetics and the platelet GP IIb-IIIa receptor.
Zablocki JA; Miyano M; Garland RB; Pireh D; Schretzman L; Rao SN; Lindmark RJ; Panzer-Knodle SG; Nicholson NS; Taite BB
J Med Chem; 1993 Jun; 36(13):1811-9. PubMed ID: 8515420
[TBL] [Abstract][Full Text] [Related]
7. Synthetic RGD peptides derived from the adhesive domains of snake-venom proteins: evaluation as inhibitors of platelet aggregation.
Lu X; Deadman JJ; Williams JA; Kakkar VV; Rahman S
Biochem J; 1993 Nov; 296 ( Pt 1)(Pt 1):21-4. PubMed ID: 8250845
[TBL] [Abstract][Full Text] [Related]
8. [Antiaggregation activity of arachidonic acid conjugates with neurotropic peptides proglyprol and semax].
Bezuglov VV; Gretskaia NM; Vasil'eva TM; Petrukhina GN; Andreeva LA; Miasoedov NF; Makarov VA
Eksp Klin Farmakol; 2014; 77(6):30-2. PubMed ID: 25102733
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis of novel tryptophan derivatives for antiplatelet aggregation activity based on tripeptide pENW (pGlu-Asn-Trp).
Xie Z; Feng S; Wang Y; Cao C; Huang J; Chen Y; Kong Y; Li Z
Eur J Med Chem; 2015 Sep; 102():363-74. PubMed ID: 26298494
[TBL] [Abstract][Full Text] [Related]
10. Design and Synthesis of Non-peptide RGD Mimics for Evaluation of Their Utility as Anti-platelet Agents.
Higuchi K; Hikita H; Murayama A; Yuri D; Kobayakawa N; Takahashi T; Kojima S; Ueno H; Hatakeyama T; Kato A; Tayu M; Oyama E; Sugiyama S; Ishii K; Takahashi H; Kawasaki T
Chem Pharm Bull (Tokyo); 2016; 64(12):1726-1738. PubMed ID: 27904082
[TBL] [Abstract][Full Text] [Related]
11. [Fibrin-depolymerization activity and the antiplatelet effect of small cyclic and linear proline-containing peptides].
Pastorova VE; Liapina LA; Alshmarin IP; Ostrovskaia PU; Gudasheva TA; Lugovskoĭ EV
Izv Akad Nauk Ser Biol; 2001; (5):593-6. PubMed ID: 15926323
[TBL] [Abstract][Full Text] [Related]
12. Prediction of potential protein-protein interaction sites from amino acid sequence. Identification of a fibrin polymerization site.
Kini RM; Evans HJ
FEBS Lett; 1996 Apr; 385(1-2):81-6. PubMed ID: 8641473
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and anti-aggregatory activity of linear retro-inverso RGD peptides.
Dal Pozzo A; Fagnoni M; Bergonzi R; Vanini L; de Castiglione R; Aglio C; Colli S
J Pept Res; 2000 Jun; 55(6):447-54. PubMed ID: 10888201
[TBL] [Abstract][Full Text] [Related]
14. Design of a new class of orally active fibrinogen receptor antagonists.
Klein SI; Molino BF; Czekaj M; Gardner CJ; Chu V; Brown K; Sabatino RD; Bostwick JS; Kasiewski C; Bentley R; Windisch V; Perrone M; Dunwiddie CT; Leadley RJ
J Med Chem; 1998 Jul; 41(14):2492-502. PubMed ID: 9651154
[TBL] [Abstract][Full Text] [Related]
15. Chemical synthesis and structural characterization of the RGD-protein decorsin: a potent inhibitor of platelet aggregation.
Polverino de Laureto P; Scaramella E; De Filippis V; Marin O; Doni MG; Fontana A
Protein Sci; 1998 Feb; 7(2):433-44. PubMed ID: 9521121
[TBL] [Abstract][Full Text] [Related]
16. Circular dichroism studies of type III collagen mimetic peptides with anti- or pro-aggregant activities on human platelets.
Pêcher J; Pires V; Djaafri I; Da Nascimento S; Fauvel-Lafève F; Legrand C; Sonnet P
Eur J Med Chem; 2009 Jun; 44(6):2643-50. PubMed ID: 19056149
[TBL] [Abstract][Full Text] [Related]
17. A three-residue cyclic scaffold of non-RGD containing peptide analogues as platelet aggregation inhibitors: design, synthesis, and structure--function relationships.
Stavrakoudis A; Bizos G; Eleftheriadis D; Kouki A; Panou-Pomonis E; Sakarellos-Daitsiotis M; Sakarellos C; Tsoukatos D; Tsikaris V
Biopolymers; 2000-2001; 56(1):20-6. PubMed ID: 11582574
[TBL] [Abstract][Full Text] [Related]
18. A novel surface-active peptide derivative exhibits in vitro inhibition of platelet aggregation.
Ramesh CV; Jayakumar R; Puvanakrishnan R
Peptides; 1998; 19(10):1695-702. PubMed ID: 9880074
[TBL] [Abstract][Full Text] [Related]
19. Novel fibrinogen receptor antagonists. RGDF mimetics, derivatives of 4-(isoindoline-5-yl)amino-4-oxobutyric acid.
Krysko AA; Chugunov BM; Malovichko OL; Andronati SA; Kabanova TA; Karaseva TL; Kiriyak AV
Bioorg Med Chem Lett; 2004 Nov; 14(22):5533-5. PubMed ID: 15482918
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and antiaggregatory activity of antiflammin related peptides.
Marastoni M; Scaranari V; Salvadori S; Tomatis R; Spisani S; Traniello S
Farmaco; 1991 Nov; 46(11):1265-72. PubMed ID: 1811615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
